A proof-of-concept methodology to validate the in situ visualization of residual disease using cancer-targeted molecular agents in fluorescence-guided surgery.
Proc SPIE Int Soc Opt Eng
; 112222020.
Article
in En
| MEDLINE
| ID: mdl-34054189
Full text:
1
Database:
MEDLINE
Language:
En
Year:
2020
Type:
Article